A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Nutritional and metabolic diseases; Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 27 Apr 2017 Status changed from recruiting to completed.
- 06 Apr 2017 Planned End Date changed from 31 Jul 2017 to 13 Apr 2017.
- 06 Apr 2017 Planned primary completion date changed from 31 Jul 2017 to 13 Apr 2017.